about
Predicting relapsing-remitting dynamics in multiple sclerosis using discrete distribution models: a population approach.Performance in population models for count data, part I: maximum likelihood approximations.Modelling overdispersion and Markovian features in count data.Pharmacokinetic-pharmacodynamic modelling of the analgesic effects of lumiracoxib, a selective inhibitor of cyclooxygenase-2, in rats.A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis.Methadone: a review of its pharmacokinetic/pharmacodynamic properties.Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies.Population pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: role of CYP3A5 genotype and formulation.Relation between acute and long-term cognitive decline after surgery: Influence of metabolic syndrome.Modelling and simulation in the development and use of anti-cancer agents: an underused tool?Semi-mechanistic modeling of the interaction between the central and peripheral effects in the antinociceptive response to lumiracoxib in rats.Target-mediated disposition model describing the dynamics of IL12 and IFNγ after administration of a mifepristone-inducible adenoviral vector for IL-12 expression in mice.Mathematical model approach to describe tumour response in mice after vaccine administration and its applicability to immune-stimulatory cytokine-based strategiesPopulation pharmacokinetic/pharmacodynamic modelling of the effects of axomadol and its O-demethyl metabolite on pupil diameter and nociception in healthy subjectsPopulation pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus.Establishing the Quantitative Relationship Between Lanreotide Autogel®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors.Correlation between anti-PD-L1 tumor concentrations and tumor-specific and nonspecific biomarkers in a melanoma mouse model.Gene therapy: a pharmacokinetic/pharmacodynamic modelling overview.Pharmacokinetic-pharmacodynamic modelling in anaesthesia.Review on modeling anti-antibody responses to monoclonal antibodies.Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications.Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities.Characterizing Gemcitabine Effects Administered as Single Agent or Combined with Carboplatin in Mice Pancreatic and Ovarian Cancer Xenografts: A Semimechanistic Pharmacokinetic/Pharmacodynamics Tumor Growth-Response Model.EGF-liposomes promote efficient EGFR targeting in xenograft colocarcinoma model.Towards patient stratification and treatment in the autoimmune disease lupus erythematosus using a systems pharmacology approach.Commentary on Pharmacometrics for Immunotherapy.Population pharmacokinetic model of lithium and drug compliance assessment.A population pharmacodynamic model for lactate dehydrogenase and neuron specific enolase to predict tumor progression in small cell lung cancer patients.Population pharmacokinetic/pharmacodynamic modelling of the analgesic effects of tramadol in pediatrics.Application of different methods to formulate PEG-liposomes of oxaliplatin: evaluation in vitro and in vivo.Comparative pharmacokinetics, tissue distributions, and effects on renal function of novel polymeric formulations of amphotericin B and amphotericin B-deoxycholate in rats.Mechanism-based modeling of the clinical effects of bevacizumab and everolimus on vestibular schwannomas of patients with neurofibromatosis type 2.Biopharmaceutic and pharmacodynamic modeling of the in vitro antiproliferative effect of new controlled delivery systems of cisplatin.Population in vitro-in vivo correlation model for pramipexole slow-release oral formulations.Semi-mechanistic description of the in-vitro antiproliferative effect of different antitumour agents.Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice.Modeling Respiratory Depression Induced by Remifentanil and Propofol during Sedation and Analgesia Using a Continuous Noninvasive Measurement of pCO2.Intrahepatic injection of recombinant adeno-associated virus serotype 2 overcomes gender-related differences in liver transduction.Population Pharmacokinetic Analysis of Lanreotide Autogel/Depot in the Treatment of Neuroendocrine Tumors: Pooled Analysis of Four Clinical Trials.Hematological response of topotecan in tumor-bearing rats: modeling of the time course of different cellular populations.
P50
Q31138740-0C2C585C-5284-44AA-BBF1-317FC52CD9DAQ33490174-92DDD460-4B97-41A2-9E9E-2A12D36013AEQ33508253-1A964EEF-E8E7-453C-B1E5-004920549743Q33661085-4AF56828-648A-4291-9ABC-EB690DF70AECQ33729213-81949A6B-577D-44B6-81EB-487A4E7407D7Q33989899-27CA1F1D-697D-4A29-AF2E-D7FBEDE1F1B8Q35178048-D3FFD0B2-C155-4297-809E-EC0D8FBD05CBQ36125433-50BCA2D9-FCC9-4526-A6EE-CCCDFAA9AF28Q36244956-7B2385B9-4D43-4111-87E0-B02D97D9F2C6Q36285351-C84195E4-91B2-4B82-BDC0-D5C65F68960BQ36331512-C520225B-88FC-4483-9DC0-92D71EBC3DBDQ36502390-869500DA-9E38-4080-8771-A3919D31DB68Q36951914-F981EE5E-9104-4E3C-9985-A5E52B23D112Q37030723-CCDAEDAE-F564-4C0F-8C38-714AB4944B24Q37409907-15A486F3-401D-4B7A-B7B8-8FB025C49123Q37600371-27779025-7E50-4DE7-A8F4-D7FFD5E76446Q37718304-DBA5AA23-DE1E-42EE-9B3C-17D164467DE0Q37729939-B77D1670-CC2D-4D45-9FC5-AEEA43C64B36Q38164107-D1FE97D4-0545-4D60-BC02-5C11D47D82E1Q38229813-E7E42D67-5FDB-4351-BA59-8F497A90DD20Q38289581-DEBC8622-0CB6-497C-B4AF-39D5CF6BC467Q38351470-AF490156-D451-4253-9333-9267D8BFF8B4Q38724056-C1F9A712-6094-4350-9F8A-372F93CD4075Q38792917-BD1ED4E5-AEC3-4DA6-92D9-E120A647CDD6Q38808690-A3660C89-80E2-4E0F-8939-01C6167BDFE4Q39082975-51FECE5D-C232-4CEF-8886-246993C079CBQ39171975-A4D83A76-C87F-4658-9EFC-07EABC322F09Q39302674-398E0C2C-0DE2-4EE7-976D-2363E1D1945AQ39346524-00469B51-7C54-4D15-8AC3-524FCF571959Q39389492-A6502F7D-8EE6-495F-A80C-F0158612B639Q39473415-5F8771F1-5AC1-48A0-90CA-DA94A2BEA21DQ39794311-F83B3F59-E6BB-4024-BFA9-BF8A53278997Q39843732-56F6BCC7-16D1-4AF8-B24E-7689466CA940Q39915754-5719D330-BC78-42C3-9F47-9A9B5BB2C2D3Q40033994-F1F1AD2E-DD33-4AD2-BAB4-4992B694DBAAQ40044519-F9F540A1-53CA-48FD-A860-5B50A8163006Q40218663-DC04CE3B-170A-474D-BBE6-D69167F27BBDQ40315949-6E5B70E1-2E00-40A5-962A-9A813AE62AC9Q40489239-9A055BB7-51CD-44BE-9315-E69571E26034Q40556860-4C93EA62-27DF-4FCE-B4A0-E0F1DD39FEB1
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Iñaki F Trocóniz
@es
Iñaki F. Trocóniz
@en
Iñaki F. Trocóniz
@sl
type
label
Iñaki F Trocóniz
@es
Iñaki F. Trocóniz
@en
Iñaki F. Trocóniz
@sl
altLabel
I Troconiz
@en
IF Troconiz
@en
Inaki F. Troconiz
@en
Inaki F. Trocóniz
@en
Inaki Troconiz
@en
Inaki Trocóniz
@en
Iñaki F. Troconiz
@en
Iñaki F. Trocóniz
@en
Iñaki Troconiz
@en
Iñaki Trocóniz
@en
prefLabel
Iñaki F Trocóniz
@es
Iñaki F. Trocóniz
@en
Iñaki F. Trocóniz
@sl
P1053
I-1740-2017
P106
P1153
21738750900
P21
P31
P3829
P496
0000-0003-3700-8658
P569
2000-01-01T00:00:00Z